Free Trial

Smith & Nephew (LON:SN) Stock Price Crosses Above Two Hundred Day Moving Average - Time to Sell?

Smith & Nephew logo with Medical background

Shares of Smith & Nephew plc (LON:SN - Get Free Report) crossed above its two hundred day moving average during trading on Friday . The stock has a two hundred day moving average of GBX 1,050.36 ($14.34) and traded as high as GBX 1,113 ($15.20). Smith & Nephew shares last traded at GBX 1,107 ($15.12), with a volume of 701,549 shares trading hands.

Smith & Nephew Trading Up 0.4%

The company has a quick ratio of 0.84, a current ratio of 2.51 and a debt-to-equity ratio of 70.22. The firm's 50 day simple moving average is GBX 1,078.66 and its two-hundred day simple moving average is GBX 1,051.34. The stock has a market cap of £12.18 billion, a P/E ratio of 40.02, a price-to-earnings-growth ratio of 0.46 and a beta of 0.62.

Insider Activity

In other news, insider Jeremy (Jez) Maiden purchased 1,855 shares of Smith & Nephew stock in a transaction dated Thursday, May 1st. The stock was bought at an average price of GBX 1,070 ($14.61) per share, with a total value of £19,848.50 ($27,104.33). Company insiders own 0.19% of the company's stock.

Smith & Nephew Company Profile

(Get Free Report)

Smith & Nephew plc, together with its subsidiaries, develops, manufactures, markets, and sells medical devices and services in the United Kingdom and internationally. It operates through three segments: Orthopaedics, Sports Medicine & ENT, and Advanced Wound Management. The company offers knee implant products for knee replacement procedures; hip implants for revision procedures; trauma and extremities products that include internal and external devices used in the stabilization of severe fractures and deformity correction procedures; and other reconstruction products.

Further Reading

Should You Invest $1,000 in Smith & Nephew Right Now?

Before you consider Smith & Nephew, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Smith & Nephew wasn't on the list.

While Smith & Nephew currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

20 High-Yield Dividend Stocks that Could Ruin Your Retirement Cover

Almost everyone loves strong dividend-paying stocks, but high yields can signal danger. Discover 20 high-yield dividend stocks paying an unsustainably large percentage of their earnings. Enter your email to get this report and avoid a high-yield dividend trap.

Get This Free Report
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

3 Made in America Stocks Under $20 You Need to See!
3 Cheap Growth Stocks Set to Explode This Summer
The Next NVIDIA? Quantum Computing Stocks Set for Explosive Growth

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines